← Back to Screener
Apimeds Pharmaceuticals US, Inc. (APUS)
Price$1.52
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-108.10%
Price vs S&P 500 (4W)-24.40%
VGM Score4.33
Market Capitalization$21.28M
All Metrics
Book Value / Share (Quarterly)$12.19
Cash Flow / Share (Quarterly)$-0.08
Price vs S&P 500 (YTD)-100.18%
EPS (TTM)$-4.58
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-4.58
EPS (Annual)$-0.55
ROI (Annual)-3.73%
Cash / Share (Quarterly)$0.29
ROA (Last FY)-3.66%
EBITD / Share (TTM)$-1.50
Cash Flow / Share (Annual)$-0.08
P/B Ratio0.14x
P/B Ratio (Quarterly)0.13x
Net Income / Employee (Annual)$-3,000,600
Net Interest Coverage (TTM)-48.72x
ROA (TTM)-13.03%
EPS Incl Extra (Annual)$-0.55
Current Ratio (Annual)1.31x
Quick Ratio (Quarterly)1.09x
3-Month Avg Trading Volume0.10M
Revenue / Employee (TTM)$0
52-Week High$40.31
EPS Excl Extra (Annual)$-0.55
26-Week Price Return-92.17%
Quick Ratio (Annual)1.09x
13-Week Price Return-92.03%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)1.31x
Enterprise Value$27.23M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.29
3-Month Return Std Dev262.57%
Net Income / Employee (TTM)$-3,000,600
ROE (Last FY)-3.91%
Net Interest Coverage (Annual)-23.71x
EPS Basic Excl Extra (Annual)$-0.55
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-4.58
Revenue / Share (Annual)$0.00
Year-to-Date Return-91.40%
5-Day Price Return-6.00%
EPS Normalized (Annual)$-0.55
Month-to-Date Return-25.00%
EBITD / Share (Annual)$-0.54
LT Debt / Equity (Annual)8.37x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.58
P/B Ratio (Annual)0.13x
Book Value / Share (Annual)$12.19
Price vs S&P 500 (13W)-101.78%
Beta1.45x
Revenue / Share (TTM)$0.00
52-Week Low$1.24
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
APUSApimeds Pharmaceuticals US, Inc. | — | — | F | $1.52 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered bee venom-based therapy targeting inflammation and pain associated with osteoarthritis and multiple sclerosis. The company's lead candidate is already marketed in South Korea under the brand name Apitoxin for osteoarthritis treatment, providing clinical validation of the therapeutic approach.